Difference between revisions of "Cyclophosphamide (Cytoxan)"
Jump to navigation
Jump to search
m (→References) |
m (→References) |
||
Line 153: | Line 153: | ||
[[Category:Drugs FDA approved in 1959]] | [[Category:Drugs FDA approved in 1959]] | ||
+ | [[Category:WHO Essential Cancer Medicine]] |
Revision as of 18:31, 5 June 2016
General information
Class/mechanism: Alkylating agent; transformed primarily in the liver to active metabolites which alkylate and crosslink DNA.[1][2]
Route: IV, PO
Extravasation: irritant, n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute lymphocytic leukemia
- Anaplastic large cell lymphoma
- Bladder cancer
- Bone cancer
- Breast cancer
- Burkitt lymphoma
- Central nervous system (CNS) cancer
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- CNS lymphoma
- Coagulopathies
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Large granular lymphocytic leukemia
- Light-chain (AL) amyloidosis
- Mantle cell lymphoma
- Marginal zone lymphoma
- Mediastinal gray-zone lymphoma
- Multiple myeloma
- Neuroendocrine tumors
- Peripheral T-cell lymphoma
- Primary mediastinal B-cell lymphoma
- Prostate cancer
- Small cell lung cancer
- Thymoma
- Transformed lymphoma
- Transplant conditioning regimens
- Waldenström macroglobulinemia
Patient drug information
- Cyclophosphamide (Cytoxan) patient drug information (Chemocare)[3]
- Cyclophosphamide (Cytoxan) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 11/16/1959: initial FDA approval
Also known as
Synonyms | |||||||
---|---|---|---|---|---|---|---|
Alkyloxan | Biodoxan | Carloxan | Ciclofosfamida | Ciclofosfamida Filaxis | Ciclofosfamida Martian | Ciclokebir | Cyclam |
Cycloblastin | Cycloblastine | Cyclo Cell | Cycloferon | Cyclomide | Cyclophar | Cyclophospham | Cyclophosphamid |
cyclophosphamide monohydrate | Cyclophosphamid Farmos | Cyclophosphan | Cyclophosphan Lens | Cyclostin | Cycloxan | Cycram | Cydoxan |
Cyklofosfamid | Cytophosphan | Cytoxan | Cytoxan Lyophilized | Endoxan | Endoxan-N | Endoxana | Endoxan Asta |
Formitex | Genoxal | Genuxal | Hidrofosmin | Ledoxan | Ledoxina | Lyophilized Cytoxan | Neosar |
Oncomide | Oncophos | Procytox | Revimmune | Sendoxan | Syklofosfamid | Trav Cyclophosphamide | Tymtran |
Zycram |
References
Categories:
- Drug index
- Chemotherapy
- Intravenous chemotherapy
- Irritant chemotherapy
- Oral chemotherapy
- Alkylating agents
- Nitrogen mustards
- Acute lymphocytic leukemia medications
- Anaplastic large cell lymphoma medications
- Bladder cancer medications
- Bone cancer medications
- Breast cancer medications
- Burkitt lymphoma medications
- Central nervous system (CNS) cancer medications
- Central nervous system (CNS) lymphoma medications
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Coagulopathy medications
- Diffuse large B-cell lymphoma medications
- Follicular lymphoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Large granular lymphocytic leukemia medications
- Light-chain (AL) amyloidosis medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Multiple myeloma medications
- Neuroendocrine tumor medications
- Peripheral T-cell lymphoma medications
- Primary mediastinal B-cell lymphoma medications
- Prostate cancer medications
- Small cell lung cancer medications
- T-cell lymphoma medications
- Thymoma medications
- Transformed lymphoma medications
- Transplant medications
- Waldenström macroglobulinemia medications
- Drugs FDA approved in 1959
- WHO Essential Cancer Medicine